Autres langues Arvinas, Inc.

Actions

ARVN

US04335A1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/04/2024			Varia. 5j.	Varia. 1 janv.
33,45 ^USD	+0,03 %		-8,93 %	-18,73 %

15/04	ARVINAS, INC. : HC Wainwright optimiste sur le dossier	ZM
12/04	ARVINAS, INC. : HC Wainwright reste à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arvinas : 2024 Proxy Statement	17/04
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	12/04
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	12/04
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	11/04
Novartis : accord de licence dans le cancer de la prostate	11/04
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	11/04
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	11/04
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten	11/04
Novartis licenses Arvinas' cancer drug for up to $1 billion	11/04
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	11/04
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	11/04
Arvinas Appoints Noah Berkowitz as Chief Medical Officer	18/03
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	18/03
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee	18/03
Arvinas to Participate in Upcoming Investor Conferences	04/03
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	27/02
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	27/02
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	27/02
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Arvinas, Inc.

Actions

ARVN

US04335A1051

Autres langues

Filtres